EBNA size polymorphism can be used to trace Epstein-Barr virus spread within families.

Por Gratama, J W, Oosterveer, M A, Klein, G, Ernberg, I
Publicado em 1990

Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency.

Por Gratama, J W, Oosterveer, M A, Zwaan, F E, Lepoutre, J, Klein, G, Ernberg, I
Publicado em 1988

Circulating endothelial cells in oncology: pitfalls and promises

Por Strijbos, M H, Gratama, J W, Kraan, J, Lamers, C H, Bakker, MA den, Sleijfer, S
Publicado em 2008

Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells

Por Kraan, J, van den Broek, P, Verhoef, C, Grunhagen, D J, Taal, W, Gratama, J W, Sleijfer, S
Publicado em 2014

Systematic review of the safety and efficacy of contrast injection via venous catheters for contrast-enhanced computed tomography

Por Buijs, S.B., Barentsz, M.W., Smits, M.L.J., Gratama, J.W.C., Spronk, P.E.
Publicado no Eur J Radiol Open (2017)

Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.

Por Gratama, J W, Bruin, R J, Lamers, C H, Oosterom, R, Braakman, E, Stoter, G, Bolhuis, R L
Publicado em 1993

Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases

Por Lalmahomed, Z S, Mostert, B, Onstenk, W, Kraan, J, Ayez, N, Gratama, J W, Grünhagen, D, Verhoef, C, Sleijfer, S
Publicado no Br J Cancer (2015)

Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.

Por Goey, S. H., Gratama, J. W., Primrose, J. N., Ward, U., Mertelsmann, R. H., Osterwalder, B., Verweij, J., Stoter, G.
Publicado em 1996

Blood volume and body fluid compartments in lambs with aortopulmonary left-to-right shunts.

Por Gratama, J W, Dalinghaus, M, Meuzelaar, J J, Gerding, A M, Koers, J H, Zijlstra, W G, Kuipers, J R
Publicado em 1992

The influence of cytomegalovirus carrier status on lymphocyte subsets and natural immunity.

Por Gratama, J W, Kardol, M, Naipal, A M, Slats, J, Den Ouden, A, Stijnen, T, D'Amaro, J, The, T H, Bruning, J W
Publicado em 1987

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.

Por Goey, S. H., Eggermont, A. M., Punt, C. J., Slingerland, R., Gratama, J. W., Oosterom, R., Oskam, R., Bolhuis, R. L., Stoter, G.
Publicado em 1995

Flow cytometric and morphologic studies of HNK1+ (Leu 7+) lymphocytes in relation to cytomegalovirus carrier status.

Por Gratama, J W, Kluin-Nelemans, H C, Langelaar, R A, den Ottolander, G J, Stijnen, T, D'Amaro, J, Torensma, R, Tanke, H J
Publicado em 1988

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

Por Kruit, W. H., Punt, C. J., Goey, S. H., de Mulder, P. H., Gratama, J. W., Eggermont, A. M., Bolhuis, R. L., Stoter, G.
Publicado em 1996

The effect of cytomegalovirus infection on T lymphocytes after allogeneic bone marrow transplantation.

Por Würsch, A M, Gratama, J W, Middeldorp, J M, Nissen, C, Gratwohl, A, Speck, B, Jansen, J, D'Amaro, J, The, T H, De Gast, G C
Publicado em 1985

Phenotypic study of CD4+ and CD8+ lymphocyte subsets in relation to cytomegalovirus carrier status and its correlate with pokeweed mitogen-induced B lymphocyte differentiation.

Por Gratama, J W, Langelaar, R A, Oosterveer, M A, van der Linden, J A, den Ouden-Noordermeer, A, Naipal, A M, Visser, J W, de Gast, G C, Tanke, H J
Publicado em 1989

Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting

Por Feller, N, van der Velden, V H J, Brooimans, R A, Boeckx, N, Preijers, F, Kelder, A, de Greef, I, Westra, G, te Marvelde, J G, Aerts, P, Wind, H, Leenders, M, Gratama, J W, Schuurhuis, G J
Publicado em 2013

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomusti...

Por Beije, N, Kraan, J, Taal, W, van der Holt, B, Oosterkamp, H M, Walenkamp, A M, Beerepoot, L, Hanse, M, van Linde, M E, Otten, A, Vernhout, R M, de Vos, F Y F, Gratama, J W, Sleijfer, S, van den Bent, M J
Publicado no Br J Cancer (2015)